The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus.
The effects of indomethacin on patent ductus arteriosus (PDA) were retrospectively studied by evaluating 1,600 consecutive infants less than 36 weeks gestation from 1983 to 1986. Two hundred thirteen infants were diagnosed with a PDA, and 102 infants received indomethacin. Indomethacin was associated with successful PDA closure in 81 infants (79%), with 59 infants (58%) closing after a single dose. No cases of renal failure were observed after indomethacin. Nine infants were treated despite a creatinine (Cr) value greater than or equal to 1.5 mg/dl. Cr improved in all these infants after therapy. Blood urea nitrogen values were greater than or equal to 30 mg/dl in 22 infants at the time of treatment; 18 infants (82%) improved. An intracranial hemorrhage (ICH) was detected in 23 infants (22%) by cranial ultrasound prior to indomethacin; there was no progression after treatment. Data suggest that indomethacin is highly associated with closure of a PDA, and therapy did not result in prolonged renal dysfunction or worsening ICH.
Davis
J M
JM
Department of Pediatrics (Neonatology and Cardiology), University of Rochester School of Medicine and Dentistry, N.Y.
Hendricks-Munoz
K D
KD
Hagberg
D
D
Manning
J A
JA
D058186:Acute Kidney Injury / Q000139:chemically induced*; D002543:Cerebral Hemorrhage / Q000473:pathology*; D004341:Drug Evaluation; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007677:Kidney Function Tests; D012189:Retrospective Studies
D007213:Indomethacin